2024 Annual Psychiatric Update
Information
Psychiatry has undergone notable expansion in recent years, characterized not only by innovative advancements in treatment interventions but also by an increased propensity for inclusion, engagement with the wider society, self-critique, introspection, and a conscientious reevaluation of conventional wisdom. The 2024 Annual Psychiatric Update by OPPA, “Re-imagining Mental Health: Innovations and Insights in Psychiatry” takes place in this context.
Clinicians, researchers, educators, and trainees are invited to gather for a scholarly and accessible discussion of vital subjects, including lessons in suicide prevention, the science of placebo effects, health care inequities, progressive approaches to harm reduction in involuntary care, advances in psychopharmacological management of depression and perinatal depression, nuanced examination of the ramifications of marijuana legalization on mental health, and erudite reflections on an important episode from the history of psychiatry. This conference is designed to foster thoughtful reflection into the complexities of mental health care and to enrich your psychiatric practice.
Speakers
Brian Barnett, MD
|
|
Tamara Campbell, PsyD, MD, DFAPA
|
|
Audrey Clare Farley, PhD
|
|
David A. Gorelick, MD, PhD, DLFAPA, FASAM
|
|
Kathryn T. Hall, PhD, MPH
|
|
Danielle Johnson, MD, FAPA
|
|
Nev Jones, PhD
|
|
Cheryl Wills, MD, DLFAPA
|
Agenda
Day/Time | ||
Saturday | ||
7- 9 a.m. | Registration/Visit Exhibits | |
7:30 - 8:30 a.m. |
Buffet Breakfast |
|
7:30 - 8:30 a.m. |
Medical Student Breakfast Meeting |
|
8 a.m. |
OPPA Annual Business Meeting and Installation of Officers |
|
8:55 a.m. |
Welcome and Opening Remarks - Awais Aftab, MD and Karen Jacobs, DO, 2024 Program Co-Chairs |
|
9 -10 a.m. |
Research on Placebo Effect - Meaning, Medication and Health Equity Kathryn Hall, PhD, MPH | Assistant Professor of Medicine, Part Time, Harvard Medical School, Associate Molecular Biologist, Brigham and Women’s Hospital Placebos are simulacra of drugs, devices, or surgeries that lack the active compound, function, or procedure they are designed to simulate. Administration of these “inactive” treatments can have significant therapeutic benefits called placebo effects, which accounts for their use as controls in clinical trials as comparators for active drugs, devices, or surgical interventions. Key drivers of placebo effects include the patient’s expectation and conscious or subconscious conditioning. Psychological studies demonstrated that expectations are shaped by factors intrinsic to the patient, including their past experiences and core beliefs or mindsets, and extrinsic factors including environmental cues, clinical practice and information received about a treatment. Neuroimaging studies identified consistent changes in the brain in response to placebo treatment that suggest that placebo effects work by integrating incoming information about extrinsic factors with prior experience and mindsets to update expectations of treatment benefit. When expectations are negative, they can result in negative outcomes, termed, “nocebo effects.” In racially discordant clinical dyads, absence of placebogenic and presence of nocebogenic factors can erode treatment efficacy exacerbating health inequities. For many years, placebo effects were viewed as superfluous nuisance variables to be ignored, marginalized, and simply “controlled for” in clinical trials. Increasing failures in clinical trials due to high placebo response coupled with advances in placebo studies reinforce the value of understanding the mechanism of action of placebo effects and harnessing these effects in clinical care and clinical trials. |
|
10 -11 a.m. |
Integrated Mental Health and Suicide Prevention - What We Can Learn from the Veteran's Health Administration Tamara Campbell, PsyD, MD | Executive Director, VA Office of Mental Health and Suicide Prevention, Veterans Health Administration, U.S. Department of Veterans Affairs |
|
11-11:30 a.m. |
Break / Visit Exhibits |
|
11:30 a.m. - 12:30 p.m. |
Psychosis, Coercion, and Civil Commitment: A Harm Reduction Approach Nev Jones, PhD | Assistant Professor, University of Pittsburgh, School of Social Work This presentation will review the potential harms of involuntary (or civil) psychiatric commitment and present a series of strategies aimed not at abolition or elimination but rather “harm reduction,” including in cases in which civil commitment is unavoidable in the contemporary practice and policy landscape. |
|
12:30 -1:30 p.m. |
Buffet Lunch / Visit Exhibits |
|
1:30 - 2:30 p.m. |
Flash Talks An integration of several five-minute Flash Talk presentations by resident/fellow members, from multiple training programs throughout Ohio, who will share novel research to improve quality of care in psychiatric treatment. Flash Talks are designed to quickly engage participants by sharing an idea, methodologies and outcomes in a clear and concise manner. |
|
2:30 - 3:30 p.m. |
Human Trafficking, Healthcare, and Harm Reduction: Establishing a Standard of Care Cheryl Wills, MD, DFAPA | Area 4 Trustee, APA Vice Chair for Equity, Diversity and Inclusion Human trafficking is the second largest crime in the world and a public health crisis that affects at least 400,000 individuals in the U.S. and Worldwide. Healthcare is one of the only systems of care that trafficking victims interface with, yet health professionals fail to identify 88% of victims in the year before they are freed. Health professionals, boards, and legislators have been increasing training requirements for healthcare professionals so that they can become more proficient with identifying and assisting victims. This presentation will examine human trafficking, the process by which individuals are groomed for enslavement, how they present to hospitals and mental health professionals to help them. |
|
3:30 - 3:45 p.m. |
Break / Visit Exhibits |
|
3:45 - 4:45 p.m. |
Is a Psychedelic Revolution Coming to Psychiatry? Brian Barnett, MD | Assistant Professor of Psychiatry, Clinical Director—Psychiatric Treatment Resistance Program, Cleveland Clinic With the FDA currently reviewing a New Drug Application for MDMA for the treatment of post-traumatic stress disorder, psychedelic-assisted therapy appears poised to return to psychiatry by the end of the year. The aims of this talk are to help prepare attendees for this potentiality by reviewing the evidence base for psychedelic assisted therapy, discussing potential adverse effects of psychedelics, identifying populations for which risk of adverse effects is elevated, and providing an overview of anticipated implementation challenges for psychedelic assisted therapy within our healthcare system. |
|
4:45 - 6 p.m. |
Poster Presentations During this session, meeting attendees will have the opportunity to view 12 posters that ranked the highest based on scoring criteria in the poster competition organized by the Ohio Psychiatric Physicians Foundation for 2024.
|
|
6 - 6:30 p.m. |
OPPF Annual Meeting and Awards Presentation |
|
6:30 - 8 p.m.
|
|
Dinner with Special Guest Speaker: Brandon Edwin Chrostowski, Founder, President, and CEO of EDWINS Leadership & Restaurant
|
Sunday |
|
9-10 a.m. |
Perinatal Depression: Reviewing the Standard of Care and Exploring New Treatment Options Danielle Johnson, MD, FAPA | Chief Medical Officer, Lindner Center of HOPE An estimated one in seven women experience depression during or after birth but it is often undetected, untreated, or undertreated. This session will increase awareness of the screening tools, symptoms, and diagnosis of perinatal depression. The current standard of care, recent FDA approved medications for postpartum depression, and novel treatments will be discussed. |
10-10:30 a.m. |
Break / Visit Exhibits |
10:30-11:30 a.m. |
Cannabis Legalization in Ohio: Implications for the General Psychiatrist David Gorelick, MD, PhD, DLFAPA, FASAM | Professor of Psychiatry, University of Maryland School of Medicine This presentation reviews the implications for Ohio general psychiatrists of the December 2023 legalization of non-medical cannabis (not yet operational) on top of the 2016 legalization of medical cannabis, which became operational in January, 2019. It reviews the workings of the two current “Marijuana Control Programs” (including the role of physicians), the possible influence of legalization on the epidemiology of cannabis use and use disorder, the types of patients using medical or non-medical cannabis (or both) likely to be seen by a general psychiatrist, and recommended clinical approaches for managing such patients (including screening for cannabis use disorder and referral for appropriate treatment; understanding how cannabis use might influence treatment for other psychiatric disorders). |
11:30-12:30 p.m. |
Girls and Their Monsters: The Genain Quadruplets and Their Importance to our Understanding of Schizophrenia Audrey Claire Farley, PhD | Professor of History, Mount St. Mary’s University In 1954, researchers at the newly formed National Institute of Mental Health (NIMH) set out to study the genetics of schizophrenia. When they got word that 24-year-old identical quadruplets in Michigan had all been diagnosed with the mental illness, they could hardly believe it. Here seemed incontrovertible proof of hereditary transmission and, thus, a chance to bring international fame to their fledgling institution. In fact, the case of the pseudonymous Genain quadruplets was hardly so straightforward. Contrary to fawning media portrayals of a picture-perfect Christian family, the sisters had endured the stuff of nightmares. This presentation considers the quadruplets’ contributions to scientific research, as well to longstanding myths of white racial innocence. It further considers the role of the “psy” professions in obscuring racial, sexual, and religious trauma. |
Register
The preferred method of registration is online at www.ohiopsychiatry.org/annualpsychupdate. If you register by mail, please complete the Registatrion Form and send with payment to: Ohio Psychiatric Physicians Association, PO Box 400, Dublin, OH 43017. Make check payable to OPPA. Your registration is not confirmed until payment is received. Non-member psychiatrists who join OPPA/APA by April 30, will receive $150 applied to OPPA dues (please select this option on the registration form and a representative from OPPA will contact you with further details.)
Registration Rates
Registration Type | Early Bird Rate By Mar. 10 |
Regular Rate | Late Rate After Apr. 1 |
OPPA Member | $225 | $275 | $325 |
OPPA Resident-Fellow Member | $150 | $175 | $200 |
Non-Members | |||
Non-Member Psychiatrist, other Physician, APRN, or Psychologist | $375 | $400 | $450 |
Non-Member Resident-Fellow | $225 | $250 | $275 |
Counselor, Social Worker or Physician Assistant | $250 | $300 | $350 |
Add-on: | |
Printed and bound syllabus (entire program will be available online) | $15 per program/syllabi |
Sponsor a medical student to attend Saturday and Sunday education events | $125 per student |
Sat. evening dinner and speaker event |
$75 per person |
Hotel Accommodations
A limited number of rooms have been set aside until March 25 at the rate of $169 single/double, plus applicable tax at the Marriott Columbus University Area, 3100 Olentangy River Rd., Columbus, OH 43202. To reserve a room please contact the hotel ASAP at 1-800-MARRIOTT and ask for the OPPA’s room block or click HERE.
Supporters and Exhibitors
The Ohio Psychiatric Physicians Association’s Annual Psychiatric Update brings together psychiatrists and other mental health clinicians from all over Ohio to examine a broad array of topics of clinical interest and relevance to those who want to provide the best, evidence-based care possible for individuals with a mental illness, including substance use disorders. The objective is to educate and provide information on current research, cutting edge treatment options, advances in treatment in the area of psychopharmacology and more. This is an excellent opportunity for companies to interact with and/or make products and services known to hundreds of psychiatrists, advanced practice nurses, physician assistants, psychologists, social workers, clinical counselors and other mental health professionals, including some of Ohio’s most prominent psychiatric physicians in leadership roles and academia. |
(Click on image to download prospectus)
Letter To Prospective Exhibitors 2024W9 - OPPADetails About Meeting |
THANK YOU 2024 SUPPORTERS!
Platinum Supporter
|
THANK YOU 2024 EXHIBITORS!
Alkermes APA Inc. Axsome Evoke Wellness Indivior Johnson & Johnson Oasis TMS OhioHealth Hospital System Ohio Professionals Health Program OPPA/OPPF/OPPAC Optimum TMS Otsuka America Pharmaceuticals, Inc. - Digital Medicine Otsuka Pharmaceutical Otsuka - U.S. CNS Professional Risk Management Services (PRMS) Teva Medical Affairs Teva Pharmaceuticals The Recovery Village |
Electronic Syllabus
If you are a paid registrant for the 2024 Annual Psychiatric Update, click on the link below to access the learning objectives, financial relationship disclosures (if any exist), and slide handouts for each speaker.
Thank you for helping us go green!
Click HERE to access materials.